Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1991 1
2011 1
2012 3
2013 4
2014 4
2015 5
2016 2
2017 4
2018 4
2019 9
2020 11
2021 15
2022 11
2023 20
2024 19
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Airway inflammation in COPD: progress to precision medicine.
Brightling C, Greening N. Brightling C, et al. Among authors: greening n. Eur Respir J. 2019 Aug 1;54(2):1900651. doi: 10.1183/13993003.00651-2019. Print 2019 Aug. Eur Respir J. 2019. PMID: 31073084 Free article. Review.
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.
Yousuf AJ, Mohammed S, Carr L, Yavari Ramsheh M, Micieli C, Mistry V, Haldar K, Wright A, Novotny P, Parker S, Glover S, Finch J, Quann N, Brookes CL, Hobson R, Ibrahim W, Russell RJ, John C, Grimbaldeston MA, Choy DF, Cheung D, Steiner M, Greening NJ, Brightling CE. Yousuf AJ, et al. Among authors: greening nj. Lancet Respir Med. 2022 May;10(5):469-477. doi: 10.1016/S2213-2600(21)00556-7. Epub 2022 Mar 24. Lancet Respir Med. 2022. PMID: 35339234 Clinical Trial.
Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation.
Singh SJ, Baldwin MM, Daynes E, Evans RA, Greening NJ, Jenkins RG, Lone NI, McAuley H, Mehta P, Newman J, Novotny P, Smith DJF, Stanel S, Toshner M, Brightling CE. Singh SJ, et al. Among authors: greening nj. Lancet Respir Med. 2023 Aug;11(8):709-725. doi: 10.1016/S2213-2600(23)00159-5. Epub 2023 May 19. Lancet Respir Med. 2023. PMID: 37216955 Free PMC article. Review.
Response.
Daynes E, Greening NJ, Singh SJ. Daynes E, et al. Among authors: greening nj. Chest. 2025 Mar;167(3):e96-e97. doi: 10.1016/j.chest.2024.11.025. Chest. 2025. PMID: 40074503 No abstract available.
British Thoracic Society guideline on pulmonary rehabilitation in adults.
Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, Greening NJ, Heslop K, Hull JH, Man WD, Morgan MD, Proud D, Roberts CM, Sewell L, Singh SJ, Walker PP, Walmsley S; British Thoracic Society Pulmonary Rehabilitation Guideline Development Group; British Thoracic Society Standards of Care Committee. Bolton CE, et al. Among authors: greening nj. Thorax. 2013 Sep;68 Suppl 2:ii1-30. doi: 10.1136/thoraxjnl-2013-203808. Thorax. 2013. PMID: 23880483 No abstract available.
Lung volume reduction surgery versus endobronchial valves: a randomised controlled trial.
Buttery SC, Banya W, Bilancia R, Boyd E, Buckley J, Greening NJ, Housley K, Jordan S, Kemp SV, Kirk AJB, Latimer L, Lau K, Lawson R, Lewis A, Moxham J, Rathinam S, Steiner MC, Tenconi S, Waller D, Shah PL, Hopkinson NS; CELEB investigators. Buttery SC, et al. Among authors: greening nj. Eur Respir J. 2023 Apr 27;61(4):2202063. doi: 10.1183/13993003.02063-2022. Print 2023 Apr. Eur Respir J. 2023. PMID: 36796833 Free PMC article. Clinical Trial.
Lung Volumes.
Sylvester KP, Shakespeare J, Greening N. Sylvester KP, et al. Among authors: greening n. Clin Chest Med. 2025 Sep;46(3):413-423. doi: 10.1016/j.ccm.2025.04.002. Epub 2025 Jul 2. Clin Chest Med. 2025. PMID: 40769589 Review.
Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study.
Elneima O, McAuley HJC, Leavy OC, Chalmers JD, Horsley A, Ho LP, Marks M, Poinasamy K, Raman B, Shikotra A, Singapuri A, Sereno M, Harris VC, Houchen-Wolloff L, Saunders RM, Greening NJ, Richardson M, Quint JK, Briggs A, Docherty AB, Kerr S, Harrison EM, Lone NI, Thorpe M, Heaney LG, Lewis KE, Aul R, Beirne P, Bolton CE, Brown JS, Choudhury G, Bakerly ND, Easom N, Echevarria C, Fuld J, Hart N, Hurst JR, Jones MG, Parekh D, Pfeffer P, Rahman NM, Rowland-Jones SL, Thompson AR, Jolley C, Shah AM, Wootton DG, Chalder T, Davies MJ, De Soyza A, Geddes JR, Greenhalf W, Heller S, Howard LS, Jacob J, Jenkins RG, Lord JM, Man WD, McCann GP, Neubauer S, Openshaw PJ, Porter JC, Rowland MJ, Scott JT, Semple MG, Singh SJ, Thomas DC, Toshner M, Smith N, Sheikh A, Brightling CE, Wain LV, Evans RA; PHOSP-COVID Collaborative Group. Elneima O, et al. Among authors: greening nj. Int J Epidemiol. 2024 Feb 1;53(1):dyad165. doi: 10.1093/ije/dyad165. Int J Epidemiol. 2024. PMID: 39429158 Free PMC article. No abstract available.
Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization.
Flynn CA, McAuley HJC, Elneima O, Aung HWW, Ibrahim W, Ward TJC, Bourne M, Thornton TD, Mistry V, Gilbert HR, Waheed G, Wright AKA, Evans RA, Steiner MC, Brookes CL, Brightling CE, Greening NJ. Flynn CA, et al. Among authors: greening nj. NEJM Evid. 2025 Jun;4(6):EVIDoa2500012. doi: 10.1056/EVIDoa2500012. Epub 2025 Apr 30. NEJM Evid. 2025. PMID: 40305842 Clinical Trial.
T2 Biologics for Chronic Obstructive Pulmonary Disease.
Yousuf A, Ibrahim W, Greening NJ, Brightling CE. Yousuf A, et al. Among authors: greening nj. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1405-1416. doi: 10.1016/j.jaip.2019.01.036. J Allergy Clin Immunol Pract. 2019. PMID: 31076058 Review.
113 results